3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
18
Neoplasm Metastasis
14
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Recurrence
9
Ovarian Neoplasms
7
Skin Neoplasms
6
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Basal Cell
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
cemiplimab
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled